QLT Gets New Lease On Life With Multi-Pronged Deals
Executive Summary
The Canadian drug developer will be in a position to advance its lead retinoid asset and be an acquirer of choice, according to management, after completing a series of deals, including the acquisition of InSite Vision and an investment in a new company, Aralez Pharmaceuticals.
You may also be interested in...
QLT Shows Off Its Assets In Hopes Of Attracting A Suitor
The Canadian biotech has put itself on the block after a year of changes that have transformed the company from a commercial-stage entity with pipeline assets to a one-drug tax play.
With One Launch Under Way, SpringWorks Ramps Up For A Second
The company initiated a rolling submission with the US FDA for mirdametinib, a MEK inhibitor that is poised to be its second commercial product for a rare disease.
Mural Oncology Primed For IL-2 Readouts Next Year
The company, which Alkermes spun out last year, is now positioned as a pure-play oncology specialist with a focus on cytokines.